The results of this study.

The results of this study, which was funded by Cancer Research UK, The Institute of Cancer Research and the Wellcome Trust, published in Cell*.

Lead author Professor Richard Marais, a Cancer Research UK-funded scientists at the Institute of Cancer Research, said: These unexpected results give us much more insight into the BRAF drugs in humans behave These are preliminary laboratory findings, they strongly suggest that BRAF not apply to patients not apply to patients, the defects in the RAS gene have, because long-term use could accelerate tumor growth are given.